Cyxone AB (publ) announced an updated development plan that aligns with the revised strategy revealed in August 2023, aiming to bring hope to patients suffering from these conditions. In April of this year, Kjell Stenberg, a seasoned leader in the biotech industry, was appointed as the company's new CEO. In collaboration with an external team of key opinion leaders and an internal team, Dr. Stenberg reviewed the latest findings for both the rabeximod and T20K projects.

After a thorough review and careful consideration, the company has selected a set of studies to position rabeximod and T 20K as effective and safe drugs, primarily for arthritis and MS, two currently underserved markets. The immediate focus for rabeximod is to leverage its unique safety profile, demonstrated in 300 patients, and its novel mode of action by generating compelling data in collaboration with leading experts in rheumatoid arthritis in Europe. Based on this data, the objective is to secure partnerships to conduct clinical trials targeting patients who do not respond to treatment with TNFa inhibitors.

Cyxone has previously demonstrated that its drug T20K can effectively reduce inflammation in an animal model of MS when administered before or during disease progression due to specific inhibition of IL-2, a key driver of MS in humans. T20K?s good safety profile has also been demonstrated after intravenous administration in humans. Cyxone will also explore the opportunity to combine T20K with a kappa opioid receptor agonist (KORA).

KORAs can stimulate the repair of damaged myelin to restore lost nerve functions. Cyxone?s patents cover both T20K and KORA combinations.